Home/Pipeline/Pegfilgrastim Biosimilar

Pegfilgrastim Biosimilar

Oncology (Neutropenia)

PreclinicalActive

Key Facts

Indication

Oncology (Neutropenia)

Phase

Preclinical

Status

Active

Company

Meitheal Pharmaceuticals

About Meitheal Pharmaceuticals

Meitheal Pharmaceuticals is a private, commercial-stage biopharma company focused on generic injectables and biosimilars. Leveraging a partnership-driven model, it has built a diverse pipeline and product portfolio targeting therapeutic areas such as anti-infectives, oncology, diabetes, fertility, and immunology. The company emphasizes robust manufacturing, steady supply, and rapid market response to address unmet needs and improve drug affordability. Its recent expansion into biosimilars with the acquisition of YUSIMRY® and launch of products like liraglutide injection signals a strategic growth phase.

View full company profile

Therapeutic Areas

Anti-Infective Oncology Immunology & Inflammation Fertility Diabetes

Other Oncology (Neutropenia) Drugs

Drug	Company	Phase	Status
Filgrastim Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Pegfilgrastim	Epygen Biotech	Not Disclosed	Active
Biosimilar Pegfilgrastim	Strides Pharma	Development	Likely Active